Summary
A phase I study was carried out with the new aromatic retinoic acid analogue DCE, all-trans-9-(2,6-dichloro-4-methoxy-m-tolyl)-3,7-dimethyl-2,4,6,8-nonatetraenacetylester. Data from preclinical studies show that DCE has a promising anti-tumor effect. Data from others investigators show that when DCE was given to patients in daily doses, the dose-limiting toxicity. This toxicity was comprising considerable muco-cutaneous toxicity, occurred at 40 mg/day. To avoid this dose-limiting toxicity, a weekly oral treatment schedule was tested for toxicity in this study. The starting dose was 40 mg/m2 body surface, and a modified Fibonacci scheme was used for the dose escalations. A total of 20 patients entered this study, and all were evaluable for toxicity. The highest dose was 300 mg/m2. In three patients, completely reversible WHO grade 1 liver toxicity was observed. In contrast to daily doses, a once-a-week schedule produced no mucocutaneous toxicity. Pharmacokinetic measurements showed that absorption was highly unpredictable and did not increase with dose increments. Given the results of the pharmacokinetic determinations, we concluded that escalating the DCE dose would not lead to a recommendable dose for further phase II studies, and the study was subsequently discontinued.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bersha S, Rubinstein A, Paternit JR, Ngoc-Anh Le, Poliak SC, Heller B, Ginsberg N, Fleischmayer R, Brown WV (1985) Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N Engl J Med 313: 981–985
Breitman TR, Selonick SE, Collins SJ (1980) Induction of differentiation of the human promyelocytic cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 77: 2936–2940
Carter SK (1972) Study design principles for the clinical evaluation of new drugs as developed by the chemotherapy program of the National Cancer Institute. In: Staquet M (ed) The design of clinical trials in cancer therapy. Futura, Mount Kisco, NY
Clamon G, Chabot GG, Valeriote F, Davilla E, Vogel C, Gorowsky E, Birch R (1985) Phase I study and pharmacokinetics of weekly high-dose 13-cis retinoic acid. Cancer Res 45: 1874–1878
Colburn WA, Gibson DM (1985) Isotretinoin kinetics after 80 to 320 mg oral doses. Clin Pharmacol Ther 37: 411–414
Cotler S, Chen S, Macasieb T, Colburn WA (1984) Effect of route of administration and biliary excretion on the pharmacokinetics of isotretinoin in the dog. Drug Metab Dispos 12: 143–147
Daenen S, Vellenga E, Dobbenburg OA, von Halie MR (1986) Retinoic acid as antileukemic therapy in a patient with acute promyelocytic leukemia andAspergillus pneumonia. Blood 67 (2): 559–561
Daudon M (1983) Renal toxicity of glafenine in man: renal stones and acute renal failure. Ann Biol Clin (Paris) 41 (2): 105–111
Dicken CH (1982) Retinoids: a Review. J Am Acad Dermatol 1: 541–552
Dion LD, Blalock JE, Gifford GE (1987) Vitamin A-induced density dependent inhibition of L-cell proliferation. J Natl Cancer Inst 58: 795–801
Fontana JA, Rogers JSD, Durham JP (1986) The role of 13-cis retinoic acid in the remission induction of a patient with acute promyelocytic leukemia. Cancer 57: 209–217
Gerber LH, Helfgott RK, Gross EG, Hicks JE, Ellenberg SS, Peck GL (1984) Vertebral abnormalities associated with synthetic retinoid use. J Am Acad Dermatol 10: 817–823
Gibaldi M, Perrier D (1982) In: Pharmacokinetics, 2nd edn, revised and expanded. Marcel Dekker, New York
Gold EJ, Mertelsman RH, Itrii LM, Gee T, Clarkson B, Moore MAS (1983) Phase I clinical trial of 13-cis retinoic acid in myelodysplastic syndromes. Cancer Treat Rep 67: 981–986
Hänni R, Hervoueth D, Busslinger A (1979) Determination of an aromatic retinoid and its main metabolite by high-performance liquid chromatography. J Chromatogr 162: 615–621
Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD (1977) Assessment of reponse to therapy in advanced breast cancer. Eur J Cancer 13: 89–94
Hodiak E, Gadoth N, David M, Sandbank M (1986) Muscle damage induced by isotretinoin. Br Med J 293: 425–426
Hubert DD, Holiat SM, Smith WE, Baylouny RA (1983) Inhibition of transplanted carcinomas in mice by retinoids but not by vitamin C. Cancer Treat Rep 67: 1061–1065
Lotan R, Dennert G (1979) Stimulatory effects of vitamin A analogs on induction of cell-mediated cytotoxicity in vivo. Cancer Res 39: 55–58
Miller AB, Hoogstraten S, Staquet M, Winkler J (1981) Reporting results of cancer treatment. Cancer 74: 207–214
Pedersen H, Wolf H, Jensen SK, Lund F, Hansen E, Olsen PR, Sorenson BL (1984) Administration of a retinoid as prophylaxis of recurrent non-invasive bladder tumors. Scand J Urol Nephrol 18: 121–123
Rollman O, Vahlquist A (1983) Retinoid concentrations in skin, serum and adipose tissue of patients treated with etretinate. Br J Dermatol 109: 439–447
Rowland M, Tozer TN (1980) Clinical pharmacokinetics. Lea and Ferbiger Philadelphia
Sporn MB, Dunlop NM, Newton DL, Smith JM (1976) Prevention of chemical carcinogenesis by vitamin A and its analogs (retinoids). Fed Proc 35: 1332–1338
Thein R, Lotan R (1982) Sensitivity of cultured human osteosarcoma and chondrosarcoma cells to retinoic acid. Cancer Res 42: 4771–4776
Thompson S, Stern PL, Webb M, Walsh FS, Engstrom W, Evans EP, Shi WK, Hopkins B, Graham CF (1984) Cloned human teratoma cells differentiate into neuron-like cells and other cell types in retinoic acid. J Cell Sci 72: 37–64
Vahlquist A, Loof L, Nordlinder H, Rollman O, Vahlquist C (1985) Different hepatotoxicity of two oral retinoids (etretinate and isotretinoin) in a patient with palmo-plantar psoriasis. Acta Derm Venereol (Stockh.) 65: 359–362
Zonnenberg BA, Neering H, Esch EP van der (1980) Hetbasale-cellen naevus syndroom. Ned Tijdschr Geneeskd 124: 1546–1549
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zonnenberg, B.A., v. Dijk, A., Vendrik, C.P.J. et al. A phase 1 and pharmacokinetic study using the aromatic retinoic acid analogue dichloroetretinate (Ro 12-7554). Cancer Chemother. Pharmacol. 25, 279–285 (1990). https://doi.org/10.1007/BF00684886
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00684886